

SCHEDULE OF PHARMACEUTICAL BENEFITS EFFECTIVE

1 JANUARY 2012

ERRATA

(1) This Erratum corrects the entry in the 1 January 2012 Schedule for Nicabate P and Nicotinell Step 1 nicotine transdermal patches (pages 442-443). (The entries for Nicorette, Nicotinell Step 2 and Nicotinell Step 3 nicotine patches are correct.)

The Schedule entry for these products should read as shown below. The following corrections have been made:

- The note relating to the availability of Nicabate P for short-term therapy has been corrected.
- An additional item (5571F) has been listed to allow Nicotinell Step 1 patches to continue to be available with two repeats for nicotine dependence in Aboriginal and Torres Strait Islander patients for this indication and the indication has been removed from item code 3414Q.

NICOTINE

Authority required

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.

Details of the program must be specified in the initial authority application;

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.

Details of the program must be specified in the initial authority application.

Note

A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year. No applications for increased maximum quantities and/or repeats will be authorised.

Authority required

Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy.

Note

Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year.

No applications for increased maximum quantities and/or repeats will be authorised.

Benefit is improved if used in conjunction with a comprehensive support and counselling program.

5465P NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	2	..	55.22	35.40	Nicabate P	GC
-------------	--	----	---	----	-------	-------	------------	----

NICOTINE

Authority required

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who has entered a comprehensive support and counselling program.

Details of the program must be specified in the initial authority application;

Short-term sole PBS-subsidised therapy as an aid to achieving abstinence in a patient who has indicated they are ready to cease smoking and who is entering a comprehensive support and counselling program during the consultation at which this authority is requested.

Details of the program must be specified in the initial authority application.

Note

No applications for increased maximum quantities will be authorised.

Applications for increased repeats, up to a maximum of 2, may be authorised.

A maximum of 12 weeks of PBS-subsidised nicotine replacement therapy will be authorised per year.

3414Q NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	55.22	35.40	Nicotinell Step 1	NC
5572G NP	Transdermal patch releasing approximately 14 mg per 24 hours	28	55.22	35.40	Nicotinell Step 2	NC
5573H NP	Transdermal patch releasing approximately 7 mg per 24 hours	28	55.22	35.40	Nicotinell Step 3	NC

NICOTINE**Authority required**

Nicotine dependence in an Aboriginal or a Torres Strait Islander person as the sole PBS-subsidised therapy.

Note

Only 2 courses of PBS-subsidised nicotine replacement therapy will be authorised per year.

No applications for increased maximum quantities and/or repeats will be authorised.

Benefit is improved if used in conjunction with a comprehensive support and counselling program.

5571F NP	Transdermal patch releasing approximately 21 mg per 24 hours	28	2	..	55.22	35.40	Nicotinell Step 1	NC
-------------	--	----	---	----	-------	-------	-------------------	----

(2) This Erratum adds a 20 tablet pack of Apixaban for the treatment of patients undergoing total knee replacement who only require up to 10 days of therapy.

The following new item (5500L) should be added to the listing for Apixaban that appears in the Schedule on page 105 (5054B and 5061J):

APIXABAN**Authority required**

Prevention of venous thromboembolism in a patient undergoing total knee replacement who requires up to 10 days of therapy.

Note**Shared Care Model:**

For prescribing by nurse practitioners where care of a patient is shared between a nurse practitioner and medical practitioner in a formalized arrangement with an agreed management plan. Further information can be found in the Explanatory Notes for Nurse Practitioners.

Note

No applications for increased maximum quantities and/or repeats will be authorised.

5500L NP	Tablet 2.5 mg	20	101.14	35.40	Eliquis	BQ
-------------	---------------	----	----	----	--------	-------	---------	----